Biotech Values

[DewDiligence]

is mnta responsible for reimbursing 100% of [NVS’] development expenses?

MNTA’s own out-of-pocket expenses for Lovenox development have already been reimbursed by NVS. Hence, NVS is entitled to deduct what it spent on Lovenox development—including the amount paid to MNTA—until NVS has recouped its development costs. The net effect of the past and future reimbursements is that MNTA will end up paying 50% of the overall development costs of the Lovenox program.